Dobutamine stress echocardiography (DSE) is widely used to evaluate myocardial ischemia or to clarify the differential diagnosis of chest pain. DSE is often complicated by insufficient heart rate response, hypotension or other adverse events. We report the results of the assessment of a modified protocol for DSE, in which 0.5mg of intravenous atropine administration was followed by dobutamine (DOB) infusion at 10 µg/kg/min. Three hundred twenty-two consecutive patients, 172 patients studied with the modified protocol and 150 controls undergoing conventional DSE, were compared. The percentage of patients attaining target heart rate (THR) via the modified protocol was significantly increased (65% vs. 35%, P<0.0001). The percentage of patients developing hypotension (defined as a decrease in systolic blood pressure (SBP) >25mmHg) was significantly decreased (<1% vs. 19%, P<0.0001). Fewer patients required the maximum dose (40 µg/kg/min) of DOB infusion. Peak heart rate (peak HR), peak HR:THR ratio, peak SBP, and the peak rate-pressure product were higher with the modified protocol, as compared to the conventional protocol (P<0.0001). DOB requirements were significantly reduced in patients not receiving blockers (P<0.0001), but not in patients on blockers (P=NS). The prevalence of arrhythmias, SBP>250mmHg, de novo intra-ventricular gradient development (>100mmHg) and intolerable symptoms did not differ between the groups. Coronary angiography was performed in 80 patients including in 45 patients with the conventional protocol and 35 patients with the modified protocol. No significant difference in sensitivity, specificity, accuracy, positive predictive value and negative predictive value of the two protocols was observed. These results indicate that the modified protocol improves attainment of THR and prevents hypotension during DSE. Serious adverse events were not increased. (J Echocardiogr 2007; 5: 65-71) Key words: dobutamine stress echocardiography, atropine accuracy and clinical safety of each protocol.
Introduction
Dobutamine stress echocardiography (DSE) is useful in the evaluation of myocardial ischemia [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] and in the differential diagnosis of chest pain [1, 2] . DSE is more sensitive and specific for coronary artery disease than exercise testing [1] [2] [3] [4] but has similar accuracy to stress testing with nuclear scintigraphy [1, 2, [4] [5] [6] [7] . One issue that limits the sensitivity of DSE is the inability to achieve target heart rate (THR) during the test. DSE can also be complicated by dobutamine induced hypotension. Intolerable clinical symptoms and other adverse events can also interfere with the performance and interpretation of DSE.
Atropine is an antagonist of acetylcholine receptors, which has been widely used to increase heart rate. Results of atropine administration during DSE have been variable [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . We report a modified protocol for performing DSE, designed to improve the achievement of adequate heart rate (HR) response by administration of intravenous (IV) atropine prior to DOB infusion. The modified protocol was compared with the conventional DSE protocol to evaluate the diagnostic
Methods
A total of 322 consecutive DSE examinations were evaluated. Patients who had studies using the conventional DSE protocol from May 18, 2001 to May 7, 2004 , served as the control group. The modified protocol was used from May 10, 2004 until the study concluded on January 23, 2005. Patients were excluded if there was an acute myocardial infarction or if severe aortic valve stenosis, heart failure, or arrhythmias were present. The presence of a pacemaker or a resting intraventricular pressure gradient >100mmHg were also exclusion criteria. Patients requiring low dose DSE to evaluate myocardial viability were not included. Echocardiography was performed with a Sonos 5500 (Philips Medical Systems, Andover, MA.) with a broadband transducer (S3 or S4). To assess severity of intra-ventricular pressure gradients, intra-ventricular flow velocity was measured by the continuous wave Doppler method during DSE. All examinations were performed by trained echocardiographers and evaluated by experienced cardiologists.
In the conventional protocol, DOB infusion was initiated at 5 g/kg/min, followed by 10 g/kg/min after 3 minutes, and increased by 10 g/kg/min every 3min until a maximum dose of 40 g/kg/min was achieved. In the modified protocol, 0.5 mg atropine was administered intravenously prior to beginning the DOB infusion, which was initiated at 10 g/kg/min. The initial DOB infusion rate for the modified protocol was maintained for 5 min and then increased by 10 g/kg/min every 3 min, up to a maximum dose of 40 g/kg/min (DOB40). Additional atropine was not administered to patients who did not attain their THR at the maximal DOB infusion rate.
The primary end-point was attainment of THR. Secondary end-points included: development of a new or worsened wall motion abnormality, hypotension (defined as reduction of systolic blood pressure (SBP) of >25mmHg), severe hypertension (defined as a SBP >250mmHg), achievement of DOB40 but not attained THR, and intra-ventricular obstruction (defined as a pressure gradient of >100mmHg). Arrhythmias such as paroxysmal atrial fibrillation (Paf), paroxysmal atrial flutter (PAF), paroxysmal supraventricular tachycardia (PSVT), ventricular tachycardia (VT) or ventricular fibrillation (VF) were recorded. Intolerable symptoms were divided into 3 categories: chest pain with a severity >5/10, vagal symptoms (defined as paradoxical bradycardia in association with hypotension), and other symptoms. We also recorded the peak DOB dose (maxDOB) and compared this between subgroups segregated by the presence or absence of a blocker. We recorded heart rate (HR), peak heart rate (peak HR), SBP and diastolic blood pressure (DBP). The rate-pressure product (RPP) was calculated at baseline and at peak DOB dose, as was the ratio between peak HR and THR (peak HR/THR). Adverse events were monitored and compared between groups. Coronary angiography was performed at the discretion of the treating physician, from the brachial or femoral artery approach, to evaluate coronary stenosis within 6 months of DSE. Significant coronary artery disease was defined as >75% stenosis by AHA criteria. The study was approved by the Institutional Ethics Committee of Teine Keijinkai Hospital, and written informed consent was obtained from all patients who underwent the modified protocol.
Statistical analyses
All results are expressed as mean standard deviation of the subject and control groups. The MannWhitney test was used to assess difference in HR, SBP, DBP, RPP, and maxDOB. ANOVA was used to assess differences in age. Chi-square testing was used to assess differences between groups, with statistical significance defined as P<0.05.
Results
The conventional protocol was performed on 150 patients who comprised the control group. DSE with the modified protocol was performed on 172 subjects. Patient characteristics are shown in Table 1 . The groups were well matched with respect to age, gender, indication for DSE testing, and use of blockers. Dichotomous clinical end-points are compared in Table  2 . Achievement of THR was significantly higher in patients with the modified protocol compared to the conventional protocol (65% vs. 35%, P<0.0001). Hypotension occurred in only one of 172 patients premedicated with atropine compared to 28/150 patients investigated with the conventional protocol (<1% vs. 19%, P<0.0001). The number of patients requiring DOB40 was less in the group receiving the modified protocol (8% vs. 22%, P<0.0005). As no patient required DOB40 to achieve THR, those achieving THR required less than 40 g/kg/min of DOB in this study. No significant differences were observed in the development of wall motion abnormalities, intra-ventricular pressure gradients, arrhythmias, or in the percentage of patients reporting intolerable symptoms between the two test procedures.
Hemodynamic data for both groups during DSE are detailed in Table 3 . Peak HR and peak HR/THR were significantly greater during the modified protocol (P<0.0001). SBP and DBP were significantly higher at both baseline and peak stress in the modified protocol patients, as were baseline and peak RPP. MaxDOB infusion rate was significantly lower in the modified protocol, but this decrease was attributable to the patients not receiving blockers (P<0.0001). In patients receiving blocker, no significant difference in maxDOB infusion rate was observed.
Adverse events are detailed in Table 4 . The prevalence of non-sustained VT (NSVT) did not differ significantly between the groups. Sustained VT and VF were not observed in either group. Chest pain was reported by similar numbers of patients in each protocol. Vagal symptoms were seen in a small number of patients, all of whom received the conventional protocol. Miscellaneous symptoms (headache, dyspnea, nausea or back pain) were seen infrequently during the modified protocol only.
Diagnostic accuracy of both protocols are detailed in Table 5 . Significant coronary stenosis was detected in 31 of 45 patients (69%) with a positive test using the conventional protocol vs. 22 of 35 patients (63%) with the modified protocol. Sensitivity, specificity and diagnostic accuracy were not different between the two protocols.
Discussion

Clinical benefits of the modified DSE protocol
This study demonstrated that the modified DSE protocol could be performed safely and with a reduced rate of non-diagnostic test results. Pre-treatment with 0.5 mg atropine in the modified protocol also reduced the occurrence of inadequate HR response as well as adverse events such as arrhythmias and hypotension. Tsutsui et al. [20, 21] injected atropine during DSE if the heart rate had not reached 100 bpm by the time the DOB infusion had been increased to 20 g/kg/min but noted that a prolonged period was required for recovery of the heart rate. We designed the modified DSE protocol to use a very low dose of atropine, administered prior to DOB infusion, in order to avoid this complication. We hypothesized that pre-treatment with atropine would increase the heart rate, reduce DOB requirements, and decrease DOB-associated adverse events. We also hypothesized that the effect of 0.5mg atropine IV would largely dissipate during the DSE and therefore would not result in prolonged recovery times. In order to isolate the effects of atropine pre-medication on hemodynamics and adverse events, we designed our protocol without any provision for additional atropine if the THR had not been achieved by the time the DOB infusion reached a maximal rate of 40 g/kg/min. Although our protocol differed only in the small atropine pre-injection and a slight increase in the initial DOB infusion rate, our results showed a robust increase in the rate of achieved THR. The peak HR increased from 86% of the THR with the conventional DSE to 97% of THR on the modified protocol. These favorable results occurred in spite of significant reductions in the amount of DOB administered to patients. Only 8 % of patients receiving the modified protocol reached an infusion rate of DOB40, which differs from the observations in previous studies [20] [21] 24] . Tsutsui et al. [20] reported that 21% of their patients reached DOB40 when atropine was administered later during DSE. In addition, only 8% of patients on the modified protocol, in contrast to the 22% of patients on the conventional protocol, would have required additional atropine injection if we attempted to achieve THR. The modified protocol therefore, avoided the delay subsequent to injecting additional atropine at completion of the dobutamine titration.
Beta blocker exerted a striking effect upon our data, virtually eliminating the decrease in DOB requirement. Some studies have noted reduced chronotropic response to DOB in the presence of -blockers, while others have concluded that atropine still increased the heart rate via reduced vagal tone [19, [24] [25] . Only 15% of our study subjects received -blockers, compared to 20-30% of patients studied by Tsutsui et al. [20] . The increased rate of -blockers may explain the reduced effects of atropine on maxDOB in that study.
Effect on adverse reactions during the modified DSE protocol
Another important advantage of the modified protocol was a reduction in the occurrence of hypotension during DSE. Hypotension during DSE can be caused by vagal stimulation or DOB itself. Hypotension reduces the diagnostic accuracy of DSE, and may prevent successful study completion. The significant decrease in the occurrence of hypotension after pretreatment with atropine could have multiple causes. Atropine increases intrinsic sympathetic activity, and the resultant increases in heart rate and ventricular contractility can increase SBP and RPP and counteract DOB-induced vasodilation. Reduction of vagal tone by atropine may also contribute to the observed reduction in hypotension.
Modification of the DSE protocol resulted in relatively little change in the number of adverse events. Although vagal symptoms segregated exclusively to patients in the modified protocol, and miscellaneous symptoms to the conventional protocol, the overall number of events is too low to allow meaningful conclusions. Serious ventricular arrhythmias were not observed, and the overall rate of arrhythmias in each group was similar. The overall prevalence of chest pain and intolerable symptoms did not differ significantly between study subjects and controls, suggesting that safety was comparable between the conventional and modified protocols.
Diagnostic accuracy for the detection of coronary artery disease
Sensitivity, specificity and diagnostic accuracy of a conventional protocol without atropine augmentation were not very high. The trends toward improved results using the modified protocol did not reach statistical significance. This may reflect the relatively small number of patients who had coronary angiograms available for comparison. Administration of additional atropine at the end of the protocol might have improved diagnostic yields, but this was not part of Table 5 . Diagnostic parameters of conventional DSE protocol and modified DSE protocol for the detection of coronary artery disease, compared to coronary angiography our study design, which intended to observe the safety and efficacy of the modified protocol.
Study limitations
A limitation in the data collection during this study was that the duration of elapsed time in the echocardiography laboratory was not measured; this prevented any conclusions about the effect of atropine injection upon the tome-efficiency of performing DSE. We were also unable to determine if a reduction in the examination period (due to reduced need to titrate DOB) would be offset by any time increase required for the administration of atropine. The exclusion of patients with severe wall motion abnormalities means that our results cannot be generalized to this population, who often undergo low dose DSE to assess myocardial viability. Other protocols can and should be developed to optimize the safety of DSE for this high-risk population.
Future studies will be needed to ascertain whether additional atropine can be administered safely to patients who are not achieving THR and whether such doses can further improve the quality of DSE results. Combination of this DSE protocol with emerging technologies, such as strain determination [26] or contrast echocardiography [27, 28] , may improve the detection of myocardial ischemia and merits further study.
